Early Experience With Brolucizumab Treatment of Neovascular Age-Related Macular Degeneration.

IMPORTANCE: Outcome data are limited regarding early experience with brolucizumab, the most recently approved anti-vascular endothelial growth factor (VEGF) agent for the treatment of neovascular age-related macular degeneration (nAMD). OBJECTIVE: To report clinical outcomes after intravitreous injection (IVI) of brolucizumab, 6 mg, for nAMD. DESIGN, SETTING, AND PARTICIPANTS: This retrospective case series conducted at 15 private or academic ophthalmological centers in the United States included all consecutive patients with eyes treated with brolucizumab by 6 retina specialists between October 17, 2019, and April 1, 2020. EXPOSURES: Treatment with brolucizumab IVI, 6 mg. MAIN OUTCOMES AND MEASURES: Change in mean visual acuity (VA) and optical coherence tomography parameters, including mean central subfield thickness and presence or absence of subretinal and/or intraretinal fluid. Secondary outcomes included ocular and systemic safety. RESULTS: A total of 172 eyes from 152 patients (87 women [57.2%]; mean [SD] age, 80.0 [8.0] years) were included. Most eyes (166 [96.5%]) were not treatment naive, and 65.7% of these eyes (109 of 166) were switched from the prior anti-VEGF agent because of persistent fluid detected on optical coherence tomography scans. Study eyes received a mean (SD) of 1.46 (0.62) brolucizumab IVIs. The mean (SD) VA prior to starting brolucizumab was a 64.1 (15.9) Early Treatment Diabetic Retinopathy Study (ETDRS) letter score (Snellen equivalent, 20/50) and was a 63.3 (17.2) ETDRS letter score (Snellen equivalent, 20/63) at the last study evaluation (mean difference, 0.8; 95% CI, -2.7 to 4.3; P = .65). When analyzed by number of brolucizumab IVIs, the presence or absence of fluid prior to starting brolucizumab, or the presence or absence of intraocular inflammation after receiving brolucizumab, there was no difference in mean VA prior to starting brolucizumab compared with after brolucizumab IVIs or at the final study evaluation. The mean (SD) central subfield thickness in all eyes prior to starting brolucizumab was 296.7 (88.0) µm and was 269.8 (66.5) µm at the last study examination (mean difference, 26.9 µm; 95% CI, 9.0-44.7 µm; P = .003). Intraocular inflammation was reported in 14 eyes (8.1%) and was self-limited and resolved without treatment in almost half those eyes (n = 6). One previously reported eye (0.6%) had occlusive retinal vasculitis and severe loss of vision. CONCLUSIONS AND RELEVANCE: In this analysis of brolucizumab IVI for nAMD, VA remained stable, with a reduction in central subfield thickness. Intraocular inflammation events ranged from mild with spontaneous resolution to severe occlusive retinal vasculitis in 1 eye.

La identificación del enfermo con pancreatitis aguda grave. Un estudio prospectivo, comparativo entre los criterios de Ranson y los del Instituto nacional de la Nutrición "Salvador Zubirán" / Identification of the patient with severe actue pancreatitis. A prospective, comparative study between ranson's criteria and the criteria of the Salvador Zubirán national Nutrition Institute

La identificación oportuna del enfermo con pancreatitis aguda grave (PAG= puede representar un problema para el médico, que limitado en recursos debe aplicar instrumentos que requieren exámenes de laboratorio difíciles de obtener. Antes hemos propuesto una serie de parámetros que agrupados como alteraciones (criterios INNSZ) pueden identificar con razonable certeza a los enfermos con PAG. Con el fin de validar nuestro instrumento, diseñamos un estudio prospectivo comparativo entre los criterios del INNSZ y los criterios de Ranson en 78 enfermos con pancreatitis aguda. La sensibilidad , especificidad, valor predictivo positivo, valor predictivo negativo y exactitud en la identificación de PAG, fue similara entre ambos criterios con una adecuada correlación (r=0.65, p<0.001) y concordancia (z = 5.0, Kappa 0.69, p<0.001). Estos resultados validan nuestras observaciones y permiten proponer a los criterios del INN SZ como una alternativa útil, fácil de aplicar y de bajo costo en la evaluación de los enfermos con pancreatitis aguda